Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis
M Huang, J O'Shaughnessy, J Zhao, A Haiderali… - Cancer Research, 2020 - AACR
Pathologic complete response (pCR) following neoadjuvant therapy has been associated
with improved event-free survival (EFS) and overall survival (OS) in early-stage breast …
with improved event-free survival (EFS) and overall survival (OS) in early-stage breast …
Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer
GM Rauch, BE Adrada, HM Kuerer… - American Journal of …, 2017 - Am Roentgen Ray Soc
OBJECTIVE. Neoadjuvant chemotherapy is becoming the standard of care for patients with
locally advanced breast cancer. Conventional imaging modalities used for the assessment …
locally advanced breast cancer. Conventional imaging modalities used for the assessment …
18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients
Purpose Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is
commonly accepted as the gold standard to assess outcome after NAC in breast cancer …
commonly accepted as the gold standard to assess outcome after NAC in breast cancer …
[HTML][HTML] Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and …
S Han, JY Choi - Breast Cancer Research, 2020 - Springer
Background We performed a systematic review and meta-analysis to evaluate the
prognostic significance of 18 F-FDG PET and PET/CT for evaluation of responses to …
prognostic significance of 18 F-FDG PET and PET/CT for evaluation of responses to …
Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: multimodal functional imaging and multiplex cytokine analysis
S Ueda, T Saeki, A Osaki, T Yamane, I Kuji - Clinical Cancer Research, 2017 - AACR
Purpose: Bevacizumab, an antibody against endothelial growth factor, is a key but
controversial drug in the treatment of metastatic breast cancer. We, therefore, aimed to …
controversial drug in the treatment of metastatic breast cancer. We, therefore, aimed to …
The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and …
F Tian, G Shen, Y Deng, W Diao, Z Jia - European Radiology, 2017 - Springer
Objectives The aim of this meta-analysis was to evaluate the accuracy of 18 F-FDG PET/CT
in predicting the pathological response to neoadjuvant chemotherapy (NAC) in breast …
in predicting the pathological response to neoadjuvant chemotherapy (NAC) in breast …
[HTML][HTML] Pathologic complete response and its impact on breast cancer recurrence and patient's survival after neoadjuvant therapy: a comprehensive meta-analysis
H Liu, L Lv, H Gao, M Cheng - Computational and mathematical …, 2021 - hindawi.com
Objective. Earlier research has illustrated prognostic significance of pathologic complete
response (pCR) in neoadjuvant therapy (NAT) for breast cancer, whereas correlation …
response (pCR) in neoadjuvant therapy (NAT) for breast cancer, whereas correlation …
[HTML][HTML] Integrating metabolic reprogramming and metabolic imaging to predict breast cancer therapeutic responses
Y Liu, Q Zhou, S Song, S Tang - Trends in Endocrinology & Metabolism, 2021 - cell.com
Metabolic reprogramming is not only an emerging hallmark of cancer, but also an essential
regulator of cancer cell adaptation to the microenvironment. Metabolic imaging targeting …
regulator of cancer cell adaptation to the microenvironment. Metabolic imaging targeting …
Metabolic positron emission tomography in breast cancer
Breast cancer is the most common cancer among women in the United States and the
second leading cause of cancer-related deaths; approximately 12.9% of women will be …
second leading cause of cancer-related deaths; approximately 12.9% of women will be …
68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer …
L Chen, S Zheng, L Chen, S Xu, K Wu… - Journal of Nuclear …, 2023 - Soc Nuclear Med
68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT has demonstrated
promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in …
promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in …